Previous Article | Next Article 
Journal of Virology, September 1999, p. 7678-7693, Vol. 73, No. 9
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
In Vivo Replication, Latency, and Immunogenicity of
Murine Cytomegalovirus Mutants with Deletions in the M83 and M84
Genes, the Putative Homologs of Human Cytomegalovirus pp65
(UL83)
Christopher S.
Morello,1
Lee D.
Cranmer,2,
and
Deborah H.
Spector2,3,*
Departments of
Pathology1 and
Biology2 and Center For
Molecular Genetics,3 University of
California, San Diego, La Jolla, California 92093-0366
Received 16 February 1999/Accepted 7 June 1999
 |
ABSTRACT |
We previously identified two open reading frames (ORFs) of murine
cytomegalovirus (MCMV), M83 and M84, which are putative homologs of the
human cytomegalovirus (HCMV) UL83 tegument phosphoprotein pp65 (L. D. Cranmer, C. L. Clark, C. S. Morello, H. E. Farrell, W. D. Rawlinson, and D. H. Spector, J. Virol.
70:7929-7939, 1996). In this report, we show that unlike the M83 gene
product, the M84 protein is expressed at early times in the infection
and cannot be detected in the virion. To elucidate the functional
differences between the two pp65 homologs in acute and latent MCMV
infections, we constructed two MCMV K181 mutants in which either the
M83 or M84 ORF was deleted. The resultant viruses, designated
M83
and
M84, respectively, were found to replicate in NIH 3T3 cells with kinetics identical to those of the parent strain. Western blot analysis
demonstrated that except for the absence of M83 or M84 protein
expression in the respective mutants, no global perturbations of
protein expression were detected. When
M83 and
M84 were
inoculated intraperitoneally (i.p.) into BALB/c mice, both viruses
showed similar attenuated growth in the spleen, liver, and kidney.
However, only
M83 was severely growth restricted in the salivary
glands, a phenotype that was abolished upon restoration of the M83 ORF.
M83's growth was similarly restricted in the salivary glands of the
resistant C3H/HeN or highly sensitive 129/J strain, as well as in the
lungs of all three strains following intranasal inoculation. Using a
nested-PCR assay, we found that both
M83 and
M84 established
latency in BALB/c mice, with slightly decreased levels of
M83 and
M84 genomic DNAs, relative to K181, observed in the salivary glands
and lungs. Immunization of BALB/c mice with 105 PFU of
K181,
M83, or
M84 i.p. provided similar levels of protection against lethal challenge. Although immunization with 200 PFU of
M83
also provided complete protection, this dose allowed both the
immunizing and challenge viruses to establish latency in the spleen.
Our results show that the two MCMV pp65 homologs differ in their
expression kinetics, virion association, and influence on viral tropism
and/or dissemination.
 |
INTRODUCTION |
Studies of immunity to human
cytomegalovirus (HCMV) are essential for the development of vaccines
and adoptive transfer therapies for the populations most at risk for
HCMV infection and disease. Although the vigorous antibody responses
generated by the virus during infection may limit the spread of
recurrent infection, the cell-mediated responses to the virus appear to
play the dominant role in control of the acute infection and
suppression of reactivation (46, 47, 52). Investigations
into the viral gene products targeted by the host immune responses have
demonstrated that the HCMV 65-kDa tegument phosphoprotein pp65 (UL83)
is the target of strong antibody (30), cytotoxic
T-lymphocyte (CTL) (9, 39, 63), and lymphoproliferative
(5, 61) responses. Moreover, by limiting-dilution analysis
of CTLs from seropositive individuals, it was found that the frequency
of pp65-specific CTL precursors was between 1 in 12,000 and 1 in
28,000, thereby representing a significant fraction of the total
HCMV-specific CTL precursor frequency, which ranges from 1 in 7,500 to
1 in 19,000 (9). Results of another such study measuring the
lysis of fibroblasts infected with wild-type HCMV or a pp65 deletion
mutant suggested that between 70 and 90% of HCMV-specific CTL
precursors were pp65 specific (63). Although these results
implicate pp65 as a major target of CTLs, its role in protective
immunity following acute infection remains to be proven.
The function of pp65 in HCMV replication is not known. The pp65
phosphoprotein is an especially abundant component of dense bodies, but
it is also found in the tegument of infectious virions and
noninfectious enveloped particles (2). A unique bipartite nuclear localization signal causes virion-associated pp65 to be rapidly
translocated to the nucleus upon infection (17, 55), suggesting that this protein may play a role in very early events in
gene regulation. However, no transcriptional activity has been demonstrated for this protein. A kinase activity has been found associated with pp65 in several studies (10, 56), and
although Polo-like kinase 1 was recently found to bind to pp65 in
infected cells (18), pp65 itself has not been definitively
shown to be a kinase.
An HCMV deletion mutant lacking the UL83 open reading frame (ORF)
encoding pp65 has been successfully generated by Schmolke and coworkers
(56). This UL83 mutant, designated RVAd65, shows wild-type
growth in cultured fibroblasts, demonstrating that pp65 is not required
for viral replication in cell culture. Maturation of mutant virions in
infected human foreskin fibroblasts appeared to be delayed compared to
the parent virus when examined at 6 days postinfection (p.i.), though
both viruses found in the supernatant were equally infectious. When the
virion-associated kinase activities of the parent and mutant viruses
were examined in vitro, the lower-molecular-weight virion proteins of
RVAd65 were found to be underphosphorylated compared to those of the
wild-type virus.
Experiments examining HCMV antigen presentation supported the existence
of a pp65-associated kinase activity and, more notably, suggested a
novel role for pp65 in immune evasion (20). When primary
fibroblasts were infected with HCMV AD169 or RVAd65 and subjected to in
vitro lysis by immediate-early 1 (IE1)-specific CTL clones, only the
cells infected with RVAd65 were specifically lysed. The data indicated
that increased phosphorylation of IE1 threonine residues occurred in
the presence of pp65 and that this was responsible for the lack of
presentation of IE1. These results describe an immune evasion mechanism
distinct from several others described for HCMV (for a review, see
reference 26), and it will be important to determine
whether this mechanism of CTL evasion occurs in vivo.
Because of the limits of examining HCMV pathogenesis in humans, the
murine cytomegalovirus (MCMV) model of infection has provided an
experimental model for pathogenesis and immunity studies
(28). Due to the immunodominance of pp65 in HCMV infection,
our laboratory has previously identified and described the homologs of
pp65 in MCMV (13). We found that both M83, the positional
homolog of UL83 in the MCMV genome, and the adjacent M84 ORF exhibit
homology to UL83, with the deduced amino acid sequence of M84 showing
slightly stronger UL83 homology. However, M84 also exhibits significant amino acid homology to its positional homolog, UL84, a nonstructural protein possibly involved in negative regulation of the IE2
transactivator (19) and implicated in promoting viral DNA
replication (54). We also demonstrated that like pp65, the
M83 protein is a late, virion-associated protein that is the target of
humoral responses during the infection.
In this study, we began to assess the roles of M83 and M84 during MCMV
infection in order to provide some insights into the role of HCMV pp65.
We constructed two MCMV mutants in which one of these ORFs was deleted
and replaced with a selectable marker cassette. The viruses in which
M83 and M84 were deleted, designated
M83 and
M84, respectively,
were found to grow in cultured fibroblasts with kinetics equivalent to
those of the wild-type virus, demonstrating that each of these genes is
dispensable for growth in culture. However, when either virus was
inoculated into three inbred mouse strains by either the
intraperitoneal (i.p.) or intranasal (i.n.) route, its replication was
found to be attenuated.
M83, in particular, was severely restricted
for growth in the salivary glands and lungs. This phenotype was
reversed upon restoration of M83 expression. Both mutants were found to
establish latency in the spleen, salivary glands, and lungs of BALB/c
mice, where latency is defined as the presence of viral DNA detectable
by PCR in the absence of detectable infectious virus. We also examined
the immunity generated against the mutant viruses by using them to
immunize BALB/c mice prior to lethal challenge with the virulent MCMV
strain K181. We found that responses to both mutant viruses provided
protection, equal to that of the parent strain, against subsequent
lethal challenge. An i.p. dose of 200 PFU of
M83 was fully
protective against replication of the challenge virus in the spleen and
salivary glands, but this dose was still sufficient to allow the
immunizing
M83 virus as well as the challenge virus to establish latency.
 |
MATERIALS AND METHODS |
Cell culture and virus preparation.
NIH 3T3 cells (ATCC CRL
1658) were grown in Dulbecco's modified Eagle's medium (DMEM)
supplemented with 10% (vol/vol) heat-inactivated calf serum (CS) and
(per milliliter) 0.29 mg of L-glutamine, 200 U of
penicillin, 0.2 mg of streptomycin, 0.05 mg of gentamicin, and 1.5 µg
of amphotericin B (DMEM + 10% CS). Mouse embryonic fibroblasts
(MEFs) were grown in the above-described medium with 10%
heat-inactivated fetal bovine serum being substituted for the CS. The
preparation of salivary gland-derived MCMV strain K181 and tissue
culture-derived MCMV has been previously described (13, 15).
Virus was stored at
80°C until use. For analysis of virion proteins
by Western blotting, MCMV was purified by density gradient
centrifugation of tissue culture supernatants as previously described
(12).
Mice, in vivo infections, organ harvests, and MCMV plaque
assay.
Female BALB/c (H-2d) mice were
obtained from Harlan Sprague Dawley, Inc., The Jackson Laboratory, or
Simonsen Laboratories, Inc., at 5 to 6 weeks of age. Female C3H/HeN
(H-2k) mice were obtained from Simonsen
Laboratories at 5 to 6 weeks of age. Female 129/J
(H-2b) mice were obtained from The Jackson
Laboratory at 6 to 9 weeks of age. Mice were housed in
microisolator-covered cages in a vivarium (University of California,
San Diego) and given food and water ad libitum.
For i.p. infections, either salivary gland- or tissue culture-derived
MCMV K181 was diluted in phosphate-buffered saline (PBS) such that 0.5 ml of virus was injected. For i.n. inoculations, mice were lightly
anesthetized with Metofane (methoxyflurane) before 50 µl of tissue
culture-derived virus diluted in DMEM+10% CS was instilled into the
nares. On various days after infection, mice were sacrificed and organs
were removed, homogenized in a Dounce homogenizer, and stored for MCMV
titer determination as previously described (21).
Plasmid constructions.
Restriction endonucleases, T4 DNA
ligase, T4 DNA polymerase, calf intestinal alkaline phosphatase (CIP),
and the Klenow fragment of DNA polymerase were purchased from BRL Life
Technologies, Inc. (Bethesda, Md.). Phosphorylated oligonucleotide
linkers and Escherichia coli SCS110 competent cells were
purchased from Stratagene (La Jolla, Calif.). DNA fragments were gel
purified by using either GeneClean (Bio101) or Ultrafree-MC 0.45-µm
centrifugal filter devices (Millipore). The subcloning methods employed
below were carried out as described by Sambrook et al.
(53). Unless otherwise specified, plasmids were propagated
in Escherichia coli DH5
and purified by anion-exchange
chromatography, using Qiagen Maxiprep or Miniprep kits.
Construction of the lacZ/gpt plasmid pON855 was previously
described (62).
The enhanced green fluorescent
protein-puromycin-N-acetyltransferase resistance
(EGFP-puro) fusion construct was constructed by combining the pPUR
vector (Clontech, Palo Alto, Calif.) with the pEGFP-C1 C-terminal
protein fusion vector (Clontech) in a fashion similar to that
recommended by M. Prichard and G. Pari (45a). Specifically,
both vectors were first prepared from E. coli SCS110 so that
Dam-sensitive sites could be cleaved. The unmethylated pPUR DNA
was digested with BsiWI and XbaI, and the 660-bp
fragment containing the pPUR ORF from the BsiWI site 62 bp
downstream of the AUG codon to the XbaI site downstream of the stop codon was gel purified. To provide the sequences containing the HCMV immediate-early (IE) promoter-enhancer driving the EGFP ORF,
pEGFP-C1 was cleaved with BglII and XbaI and the
4.7-kbp vector fragment was gel purified. The BglII end of
this fragment is located in the multiple cloning site at the 3' end of
the EGFP ORF and allows the addition of C-terminal fusions. To
regenerate the 5' 62 bp of the puro ORF and allow ligation of this ORF
to the 3' end of EGFP, a double-stranded, synthetic adapter was
synthesized (Integrated DNA Technologies, Inc., Coralville, Iowa). This
adapter was made by annealing two 5'-phosphorylated
deoxyribonucleotides (sense, 5'-GAT CTA TGA CCG AGT ACA AGC CCA CGG TGC
GCC TCG CCA CCC GCG ACG ACG TCC CCC GGG CC-3'; antisense, 5'-GTA CGG
CCC GGG GGA CGT CGT CGC GGG TGG CGA GGC GCA CCG TGG GCT TGT ACT CGG TCA TA-3') to provide a BglII site at the 5' end, the first 62 bp of the puro ORF, and a BsiWI site at the 3' end which
connects to the remainder of the puro ORF. In a triple ligation, the
XbaI-BglII EGFP vector was ligated to the
BglII-to-BsiWI puro ORF 5' adapter and the
BsiWI-XbaI puro ORF 3' fragment. This ligation
product was used to transform SCS110 cells, and resulting transformants were screened by restriction digestion for the presence of the adapter
and the puro 3' fragment. Positive clones were sequenced by the dideoxy
method (Sequenase) across both ligation joints, and the plasmid
pEGFP.C1/puro was found to contain the puro ORF in frame with the EGFP
ORF. This plasmid was cleaved with AseI and MluI
and blunted with the Klenow fragment, and BamHI linkers were
ligated to the blunt ends. The 2.3-kbp fragment containing the HCMV IE
promoter, the EGFP-puro ORF, and the simian virus 40 polyadenylation
site (derived from pEGFP-C1) was gel purified and then ligated to
BamHI-digested pGEM-3zf(+) vector to yield pGEM-EGFP/puro.
To construct
M83, a deletion-substitution plasmid was generated by
flanking the lacZ/gpt cassette with 0.8 kbp of MCMV genome sequence from the M84 region and 1.15 kbp of M82-containing sequence. The vector M83(Stu-Xho)-pBS contains the entire M83 ORF on a
4.35-kbp XhoI (nucleotide 120962)-to-StuI
(nucleotide 116614) fragment subcloned into the XhoI and
EcoRV sites of pBluescript II KS(+) (Stratagene, La Jolla,
Calif.), with restriction site numbers in parentheses indicating the
nucleotide number from the published complete DNA sequence of MCMV
Smith strain (GenBank accession no. U68299) (48). This
vector was digested with PstI to release the M83
ORF-containing sequence from 14 bp upstream of the 3' end of M84 to 260 bp upstream from the 3' end of the M83 ORF and then recircularized to
yield pM83-5'. The single NotI and SstI sites in
the pBluescript II multiple cloning site of pM83-5' were cleaved, and a
1.15-kbp NotI (117590)-to-SstI (116438) genomic fragment, derived from the plasmid H3C(RV)-Gem (13) (which
contains the M82 ORF on a 3-kbp EcoRV fragment), was
directionally ligated in to generate pM83-flank. pM83-flank was
digested with NotI to linearize the vector in between
flanking regions. The lacZ/gpt cassette was released from
pON855 by BamHI digestion, the ends were filled in with the
Klenow fragment, and phosphorylated NotI linkers were
ligated to the filled-in ends. After linker addition and
NotI digestion, the 4.8-kbp lacZ/gpt NotI
fragment was agarose gel purified and ligated to the
NotI-digested pM83-flank vector. Resulting transformants
were analyzed by restriction enzyme analysis, and the final vector,
p
M83KO8, was selected because the transcription of the
gpt gene proceeded in the same direction as that of M84 and
M82. Prior to electroporation, p
M83KO8 was linearized with StuI and VspI to release vector sequences and
facilitate recombination.
To generate
M83-2, an M83 deletion mutant with a reconstructed 3'
end of the M84 ORF, an oligonucleotide adapter was constructed by
annealing the 28-mer M84-3' sense (5'-GCA GAA CAT CTG ATA GAA TAA AGC
TTG C-3') and the 36-mer M84-3' antisense (5'-GGC CGC AAG CTT TAT TCT
ATC AGA TGT TCT GCT GCA-3') oligonucleotides. This adapter contains the
sequence encoding the carboxy-terminal 5 amino acids of M84 followed by
two in-frame termination codons and a polyadenylation signal. This
adapter was then ligated to NotI- and
PstI-digested pM83-flank, and dideoxy sequencing confirmed that the 3' coding sequence for M84 was regenerated in the resulting clone, p
M83+link. The NotI-ended lacZ/gpt
cassette described above was then ligated to NotI-digested
p
M83+link, and a resulting clone, p
M83-2, was chosen because
gpt, M84, and M82 transcription proceeded in the same
direction. Prior to virus generation, p
M83-2 was digested as
described above for p
M83KO8.
To generate the recombination construct for
M84, the
HindIII C fragment clone of MCMV (40) was
used to isolate M84 flanking sequence on the M85 side of the ORF. The
HindIII C clone was digested with NarI and
EcoRI, blunt ended with the Klenow fragment, and ligated to
phosphorylated PstI linkers. After overnight ligation, the
NarI fragments of HindIII C were digested
with PstI and SphI and a 1.07-kbp SphI
(122951)-to-PstI (NarI at site 121876) fragment was gel purified. The plasmid pM84-5' was generated by ligating this
fragment to SphI- and PstI-digested pGEM-1
(Promega). To isolate M84 flanking sequence from the M83 region of the
genome, M83(Stu-Xho)-pBS was cut with SmaI and a
4.75-kbp SmaI fragment was gel purified and blunt-end
ligated with EcoRI linkers. The linked plasmid was digested
with EcoRI and PstI, and a 0.99-kbp PstI (120098)-to-EcoRI (SmaI at site
119105) fragment was gel purified and ligated to PstI- and
EcoRI-cut pGEM-1 to yield pM84-3'. The inserts from pM84-5'
and pM84-3' were released by digestion with the appropriate enzymes,
gel purified, and triple ligated with SphI- and
EcoRI-digested pGEM-4Z (Promega) to yield pM84-5',3'. The
lacZ/gpt cassette, which had PstI linkers ligated
onto Klenow fragment-filled BamHI ends, was ligated into
PstI-digested pM84-5',3' to yield p
M84KO2. The p
M84KO2
clone was selected by virtue of gpt transcription proceeding
in the same direction as that of M83 and M85. To restore the TATA box
of M83 into this vector, the vector pGEM-iM84/2 (13) was
digested with ApaI and blunt ended with T4 polymerase, and
PstI linkers were ligated to the blunted ends. After
digestion with PstI, a 473-bp PstI fragment from
ApaI (120571) to PstI (120098) was gel purified.
The p
M84KO2 vector was partially digested with PstI
(1), and singly cut plasmid (9.62 kbp) was gel purified and
CIP treated. The 473-bp TATA-containing PstI fragment was
ligated into the CIP-treated, singly PstI-cut p
M84KO2,
and the ligation mixture was transformed into E. coli.
Recombinant plasmids were screened by EcoRI and NarI digestion and agarose gel electrophoresis, and a clone
which contained the TATA fragment in the correct PstI site
and in the correct orientation was selected. This plasmid,
p
M84KOT-5, was digested with BamHI and
HindIII to remove vector sequences prior to electroporation.
To construct r
M83
the rescued
M83 virus
a plasmid containing a
rescue cassette was constructed such that the EGFP-puro cassette and
M83 ORF could be inserted into the
M83 genome to yield a puromycin-selectable intermediate virus with the lacZ/gpt
and EGFP-puro cassettes flanked by M84 sequences. To construct the rescue cassette vector, pON855 was digested with SstI and
BamHI and the 3.3-kbp SstI-BamHI
gpt-containing fragment gene was gel purified. The EGFP-puro
cassette was released from pGEM-EGFP/puro by BamHI
digestion, and the 2.3-kbp insert was gel purified. The EGFP-puro
BamHI fragment and the SstI-BamHI
fragment of gpt were triple ligated to SstI- and
BamHI-digested pSP72 (Promega). Because of problems
encountered with subcloning gpt sequences in E. coli strains such as DH5
and XL-1 Blue, the WB-1
(gpt-negative) strain (57) was used for
subcloning and propagating gpt-containing plasmids. WB-1
cells were electroporated with the triple-ligation mixture, using a BTX
ECM-600 electroporator in accordance with the manufacturer's
recommendations, and transformants were grown on M9 minimal medium agar
plates (1) supplemented with 100 µg of ampicillin and 100 µg of xanthine per ml. A clone, pSP-gpt/EGFP, containing both
gpt and EGFP-puro genes in the same orientation was
identified by restriction digestion. pSP-gpt/EGFP was amplified in M9
minimal medium supplemented as described above, and Maxiprep plasmid
DNA was digested with HindIII and then CIP treated. To isolate MCMV genome sequence containing M83 and flanking ORFs, the MCMV sequences of pM83X5.5 were used. The plasmid pM83X5.5 was constructed by digesting the MCMV HindIII C plasmid
with XhoI, HindIII, and DraI, gel
purifying the 5.5-kbp XhoI (115429-to-120962) fragment, and
ligating it to XhoI-digested, CIP-treated pGEM-7Zf(+) (Promega). pM83X5.5 was digested with XhoI and blunt ended
with the Klenow fragment, and HindIII linkers were
ligated to the ends. After HindIII digestion, the
5.5-kbp HindIII-linked M83 sequence was gel purified and
ligated to HindIII-digested pSP-gpt/EGFP. The
final rescue clone, pM83Res13.6, was selected after restriction digestion analysis showed that gpt, EGFP-puro, and the MCMV
M84 and M82 ORFs were transcribed in the same direction. Before
electroporation, pM83Res13.6 was digested with SstI to
release vector sequences.
For the generation of a specific antiserum to M32 protein, the 5' end
of the ORF was reconstructed to allow in-frame fusion with the
glutathione S-transferase (GST) ORF in pGEX-KG. The 5' 222 bp of the M32 ORF was amplified by PCR, in the process placing a
BamHI site just 5' of the initiating methionine codon. The
template for amplification was the plasmid pBS-4.2 H3B(rev), which
contains the entire M32 ORF on a 4.3-kbp SstI fragment (nucleotides
38900 to 43192) in pBluescript II KS(+), and the primers were 5'-M32 (5'-GCG CGG ATC CAT GTC CGC TCG AGG GCG CGC-3') and 3'-M32 (5'-GAG CTT
CTC GTG GTA CCT GAG CCA GAG GAC-3') (Integrated DNA Technologies, Inc.). Standard PCR mixtures, supplemented with 2 mM MgCl2,
were prepared with and without template DNA, using materials supplied with the GeneAmp PCR reagent kit (Perkin-Elmer) and following the
manufacturer's recommendations. Thirty cycles of PCR were carried out
(1 min at 94°C, 1 min at 55°C, and 2 min at 72°C), followed by a
10-min extension at 72°C. An approximately 250-bp product synthesized
only in the presence of template DNA was cut with BamHI and
KpnI, isolated, and ligated to BamHI- and
KpnI-cut pGEM-4Z (Promega), yielding pGEM-5'M32. Both
strands of the PCR product were sequenced. A single transition mutation
(G to A) was found at a position 222 nucleotides from the first
nucleotide of the initiating methionine codon, resulting in a change in
codon 74 of the ORF from valine to isoleucine. This change was judged to be irrelevant, and pGEM-5'M32 was cleaved with BamHI and
EcoRI and the ~250-bp fragment was isolated and ligated to
BamHI- and EcoRI-cut pGEX-KG, yielding
pGEX-5'M32. A 1.8-kbp KpnI-HindIII fragment
of pBS-4.2 H3B(rev) was isolated and ligated to KpnI- and
HindIII-cleaved pGEX-5'M32, yielding pGEX-M32.
For production of the M84 protein as a GST fusion, the 2-kbp
BamHI-EcoRI fragment of pGEM-M84 (13)
was subcloned into BamHI- and EcoRI-cut pGEX-KG
to yield pGEX-M84.
Electroporation and mutant MCMV selection.
All mutant MCMVs
were generated in NIH 3T3 cells by homologous recombination between
linearized plasmids containing selectable markers, and the K181 genome
was introduced by infection as described by Vieira and colleagues
(62). To generate the
M83, M83-2, and
M84 viruses, 30 µg of linearized plasmid was electroporated into 4 × 106 NIH 3T3 cells by using a Gene Pulser II apparatus
(Bio-Rad). DNA and cells were added in 0.4 ml to a 4-mm-gap cuvette and
pulsed with 0.22 kV and 975 µF, using the measure capacitance
function. After being pulsed, cells were seeded in 10 ml of DMEM + 10% CS in a 10-cm-diameter tissue culture dish and incubated
overnight. The following day, the electroporated cells were infected
with MCMV K181 at a multiplicity of infection (MOI) of 3 for 6 h,
the inoculum was removed, and 10 ml of fresh medium was added. Three days p.i., the supernatant from the infected cells was harvested and
clarified by low-speed centrifugation, and 50 to 500 µl of the
clarified supernatant was used to infect 75% confluent NIH 3T3 cells
in a T-75 flask. At 3 to 4 h p.i., virus was selected as described
elsewhere (62), except that 150 µg of xanthine per ml was
used. Recombinant viruses were propagated two to three times under
gpt selection conditions and then subjected to three rounds
of limiting dilution and plaque purification until virus homogeneity
was achieved.
To generate r
M83, SstI-digested pM83Res13.6 was
electroporated into NIH 3T3 cells, using a BTX ECM-600 electroporator
(Genetronics, Inc.) in accordance with the manufacturer's protocol for
C3H fibroblasts (protocol no. PR038). In brief, two identical
electroporations were carried out with 3.2 × 106 NIH
3T3 cells in 0.8 ml of DMEM (without CS). Cells and 30 µg of DNA were
added to 4-mm-gap cuvettes, the suspensions were mixed, and each was
pulsed at 300 V, 72
, and 2,500 µF. After both cuvettes were
electroporated, the cells were combined with 4 ml of DMEM+10% CS,
seeded into a 60-mm-diameter dish, and incubated at 37°C and 10%
CO2 overnight. The following day, the electroporated cells were infected with
M83 at an MOI of 3.5 for 4 h, the inoculum was removed, and 5 ml of fresh medium was added. At 3 days p.i., the
supernatant was removed and clarified, and 50 or 100 µl of the
clarified supernatant was used to infect 75% confluent NIH 3T3 cells
in a 60-mm-diameter dish for 4 h. The following day, the medium
was replaced with 4 ml of DMEM+10% CS containing 5 µg of puromycin
(Clontech) per ml. At 3 days p.i., 0.5 ml of cleared supernatant from
the first selection was used to infect another 60-mm-diameter dish of
NIH 3T3 cells for the second selection. After three rounds of puromycin
selection, plaques resulting from infection of cells without puromycin
were observed under fluorescence and EGFP-positive plaques were picked
and used to infect fresh monolayers. Resulting plaques were stained by
overlaying with DMEM+2% CS supplemented with 0.5% agarose and 0.3 mg
of 5-bromo-4-chloro-3-indolyl-
-D-galactopyranoside (X-Gal) per ml. After X-Gal staining for 5 h, clear plaques were picked and subjected to two to three rounds of limiting dilution and
plaque purification until only EGFP-negative, lacZ-negative virus remained.
Production and purification of antisera.
A rabbit antiserum
against GST-M84 purified from E. coli inclusion bodies was
generated in a naive seronegative male New Zealand White rabbit by
previously described methods (13). The resultant GST-M84
antiserum was subjected to caprylic acid precipitation and ammonium
sulfate precipitation as described by Harlow and Lane (23).
To further purify M84-specific antibodies from the serum, portions of
serum were affinity purified with nitrocellulose membrane-immobilized
M84 produced by COS-7 cells transiently expressing pcDNA3-M84.
To generate immune rabbit serum against GST-M32, a naive female New
Zealand White rabbit that was seronegative for GST-M32 was immunized
with a GST-M32 fusion protein derived from bacterial inclusion bodies
as for GST-M84. The resulting GST-M32 antiserum was prepared and
adsorbed to an E. coli DH5
-derived acetone powder as
previously described (13).
To produce a pp89-specific antiserum, BALB/c mice were intradermally
immunized three times in 2 weeks with 30 µg of a plasmid DNA vaccine
vector (pcDNA3-pp89) expressing the full-length pp89 cDNA from the HCMV
IE promoter-enhancer (21). Ten weeks following the first
immunization, mice were bled and serum fractions were prepared and
stored at
20°C until use.
Southern and Western blot analyses.
Genomic DNA from NIH 3T3
cells infected with wild-type or plaque-purified recombinant viruses
was prepared by using a commercial kit (Qiagen Blood Kit) in accordance
with the manufacturer's recommendations. Restriction digestion and
Southern blot analysis were performed on these DNAs by standard
procedures (53). MCMV genomic probes were isolated from
restriction enzyme-digested HindIII C plasmid (40), 32P labeled by random priming (Prime-It
II; Stratagene), purified by Sephadex G-50 chromatography, and
hybridized to UV-cross-linked DNA blots in Rapid-Hyb buffer (Amersham)
according to the manufacturer's recommendations.
For Western blot analysis of viral protein expression, NIH 3T3 cells
were infected at an MOI of 3 to 3.5 with the various mutants, and at
various times p.i., cells were collected and solubilized at 42°C for
10 min in Laemmli sample buffer. Solubilization at this temperature was
critical for prevention of aggregation of the M83 and M84 proteins.
Proteins were separated by electrophoresis on sodium dodecyl sulfate
(SDS)-7.5% acrylamide gels, electroblotted to nitrocellulose, and
subjected to Western analysis as previously described (13).
M83 (13) and M32 proteins were detected with their
respective rabbit polyclonal antisera (diluted 1:2,000). M84 was
detected with the rabbit anti-GST-M84 antiserum (affinity purified as
described above), and pp89 was detected with a pcDNA3-pp89-immunized mouse serum (diluted 1:1,000). Bound antibodies were detected by
horseradish peroxidase-linked anti-rabbit- or anti-mouse immunoglobulin G whole antibodies (Amersham) and enhanced chemiluminescence
(SuperSignal Substrate; Pierce Chemical Co.).
To examine the temporal expression of the M84 protein, MCMV-infected
NIH 3T3 cells were also subjected to treatment with cycloheximide (CHX)
or phosphonoacetic acid (PAA) as described previously (12). Briefly, cells were infected in the presence of CHX and at 8 h p.i. were washed three times with PBS, fed with medium without CHX, and
incubated until being harvested at 12 h p.i. PAA-treated cells
were infected and incubated in the presence of drug until being
harvested at 48 h p.i.
Growth kinetics of MCMV in cell culture.
For single-cycle
growth analysis, triplicate cultures of NIH 3T3 cells in 24-well dishes
were infected at an MOI of 3 with tissue culture-derived MCMV isolates.
After adsorption, cells were washed twice with PBS and then fed with
DMEM + 10% CS. On each day p.i., supernatants were harvested,
cleared of cellular debris as described above, and stored at
80°C
in 1% (vol/vol) dimethyl sulfoxide. For multicycle growth analysis,
triplicate cultures were infected at an MOI of 0.05 and supernatants
were harvested and stored as described above. Viral titers for entire growth experiments were determined together in plaque assays on NIH 3T3
cells as described above.
PCR detection of latent MCMV DNA.
BALB/c mice were infected
i.p. with tissue culture-derived wild-type or mutant MCMV and then
housed for 5 to 10 months to allow the resolution of the acute
infection. To confirm the absence of persistent infectious virus,
portions of the spleens of these mice were homogenized, sonicated, and
diluted prior to incubation with MEFs or NIH 3T3 cells as previously
described (44). Cells were observed for cytopathic effects
(CPE) for 10 to 14 days, and the establishment of latency was defined
as the absence of infectious virus concomitant with the presence of
MCMV DNA sequences as determined by PCR. To detect latent MCMV genomes,
DNA was extracted from the tissues of uninfected or latently infected
mice by using a commercial kit (Qiagen Tissue Kit) according to the
manufacturer's instructions for preparation of RNA-free DNA. To
prevent cross-contamination of viral DNA, dissections were performed
with autoclaved instruments and in a BioGuard hood not used for the
handling of MCMV or acutely infected mice. In addition, the groups of
mice were sacrificed on consecutive days. Spleen DNA was extracted from
only stromal fractions prepared by sedimentation as previously
described (41), whereas lung and salivary gland DNAs were
prepared from minced whole tissues. DNAs were quantified by measurement
of the optical density at 260 nm, and agarose gel electrophoresis was
used to confirm DNA concentrations and integrity.
MCMV DNA was detected by nested PCR of the IE1 region as described by
Koffron et al. (32). In the first reaction, serial dilutions
containing either 1, 0.1, or 0.01 µg of tissue DNA were amplified in
50-µl reaction volumes containing 1× PCR Buffer II (Perkin-Elmer), 3 mM MgCl2, 40 pmol each of the SY1 and SY2 primers (32), and 200 µM each deoxynucleoside triphosphate. The
manual hot-start technique was employed by withholding the 0.25 U of AmpliTaq (Perkin-Elmer) from the reaction until the thermocycler (PTC100; MJ Research) reached 85°C. Following an initial denaturation step of 96°C for 3 min, reaction mixtures underwent 20 cycles of
94°C for 30 s, 60°C for 30 s, and 72°C for 30 s
followed by a final extension of 72°C for 8 min. This reaction
amplifies a 549-bp product that spans introns 2 and 3 of IE1. One
microliter of this reaction mixture was reamplified for 30 cycles in a
second 50-µl reaction volume containing standard buffer conditions,
primers CH16 and CH17 (27), and 2.5 mM MgCl2,
using the hot-start method and the same cycling parameters as were
employed for the first reaction. This second reaction amplifies a
310-bp region of the first reaction product. Five microliters of the
reaction 2 product was analyzed by agarose gel electrophoresis on 2%
agarose (three parts NuSieve agarose [FMC BioProducts] and one part
ultrapure agarose [GIBCO Life Sciences])-Tris-borate-EDTA (TBE) gels
and ethidium bromide staining. Images were recorded by UV illumination and by using a Gel-Doc imaging system (Bio-Rad Laboratories).
To serve as a control for sensitivity of the nested PCR, the MCMV
HindIII L plasmid (40) was digested with
HindIII, phenol-chloroform extracted, and ethanol
precipitated, and the MCMV genomic insert was quantified by agarose gel
electrophoresis. Serial dilutions of the plasmid DNA were made first in
elution buffer AE (Qiagen) and then in AE containing uninfected-mouse
genomic DNA such that 5 µl, containing 25 to 0.2 copies of the MCMV
HindIII L insert and 1 µg of mouse DNA (from the same
type of tissue as that under analysis), was added to each reaction.
Optimization trials showed that the sensitivity of the assay was always
about the same regardless of the tissue or the mass of genomic DNA
(0.01, 0.1, or 1 µg) (data not shown) added. Negative controls
contained the appropriate tissue DNA from uninfected mice.
To specifically detect the
M83 genome, primers homologous to the
gpt-selectable marker were designed for nested-PCR
amplification. The first reaction amplified a 599-bp fragment of
gpt, using the primers gpt-1S
(5'-ACAGGCTGGGACACTTCACA-3') and gpt-1A
(5'-CAGGGTTTCGCTCAGGTTTG-3'), and the second reaction used
primers gpt-2S (5'-TGGCGCGTGAACTGGGTATT-3') and gpt-2A
(5'-TCCCACGGCTGTTCAATCCA-3') to amplify a 283-bp
region of the first reaction product. Amplification reactions and
cycling conditions were as described for IE1 (see above), except that the MgCl2 concentration in both reactions was 1.5 mM and
the annealing temperature for the first reaction was 58°C. The
sensitivity of the nested reaction was monitored by amplification of a
linearized gpt-containing plasmid in genomic DNA from
uninfected mice as described above.
To confirm that the genomic DNAs were undegraded and free of PCR
inhibitors,
-actin sequences were amplified from the same DNA
dilutions that were negative for MCMV DNA. A single 50-µl reaction
mixture containing primers BA-1 and BA-2 (27), 2.5 mM
MgCl2, and the composition described above was amplified by the hot-start procedure followed by 35 to 40 cycles of the conditions described above for IE1.
 |
RESULTS |
M84 protein is expressed at early times p.i. and is not detectable
in the virion.
We previously showed by Northern blot analysis that
the M83 gene product was likely encoded by a 5-kb mRNA that was
detectable at 24 to 48 h p.i. and that M83 protein was expressed
with late gene kinetics and phosphorylated in vivo (13). We
also showed that the M84 gene product was likely encoded by a 6.9-kb
transcript that was directed by either of the TATA boxes located just
5' of the M84 ORF (13). This transcript was detectable at
8 h p.i., suggesting that it belonged to the early class of genes.
To determine the kinetics of M84 protein expression, we used Western
blot analysis and a rabbit polyclonal antiserum to GST-M84 to examine
whole-cell lysates prepared from NIH 3T3 cells infected with MCMV at a
high MOI and harvested at 8, 24, and 48 h p.i. We found that
solubilization of cell lysates at 100°C in Laemmli buffer resulted in
aggregation of more than 99% of the M84 protein into an insoluble mass
(data not shown). The M83 protein was also found to aggregate somewhat upon boiling, resulting in M83-immunoreactive species migrating to
positions corresponding to 125, 105, and 70 kDa and often to greater
than 200 kDa (13). However, when lysates were solubilized at
42°C, single immunoreactive 105- and 65-kDa species were detected with the M83- and M84-specific antisera, respectively (Fig.
1).

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 1.
Kinetics of M84 protein expression and absence of virion
association. NIH 3T3 cells were infected with K181 at an MOI of 3, and
at 8, 24, and 48 h p.i., cells were harvested and whole-cell
lysates were prepared as described in Materials and Methods. Cells were
also treated for the first 8 h of infection with CHX before the
12-h-p.i. harvest or were infected and incubated in the presence of PAA
until the 48-h-p.i. harvest. Western blots of lysates and purified
virions (Vir.) were probed with an affinity-purified rabbit antiserum
to GST-M84 or a GST-M83-specific antiserum. Each panel depicts the same
blot, and lanes are numbered at the bottom. Lanes 8 to 10 depict lanes
5 to 7 after prolonged exposure, and lanes 11 to 13 show lanes 5 to 7 after the blot was stripped and reprobed with the M83 antiserum. Un.,
uninfected. Positions of molecular mass markers are shown on the
left.
|
|
As seen in Fig. 1, a high level of M84 protein was detected at 8 h
p.i., with a subsequent steady decline over the 48-h infection period
observed. Infection for 8 h in the presence of CHX and a
subsequent 4-h release from the drug resulted in an M84 protein expression level (lane 2) at least as high as the level found at 8 h p.i. without the drug (lane 3). When cells were infected in the
presence of PAA, which limits expression to IE and early proteins, M84
protein was detectable at a level approximately 50% of that seen at
48 h p.i. in the absence of the drug (lane 6).
To determine whether M84 was associated with virions, we purified
virions from the tissue culture supernatant of MCMV-infected NIH 3T3
cells by density gradient centrifugation and analyzed the associated
proteins by Western blotting with the anti-GST-M84 antiserum as a
probe. Figure 1 shows that no M84-specific protein was detected in the
virions (lane 7), even when the blot was overexposed (lane 10) or
analyzed with more-sensitive detection reagents, such as SuperSignal
Blaze (Pierce Chemical Co.) (data not shown). As a control, we
documented that M83 protein was readily detected on the same blot with
an M83-specific rabbit antiserum (lane 13). The results presented here,
coupled with those described previously (13), show that
although both M83 and M84 exhibit significant amino acid homology to
the HCMV pp65 matrix protein (UL83), their properties are quite
different. The M83 protein is expressed at late times in the infection
cycle and is incorporated into the virion, while M84 is a nonstructural
protein expressed at early times p.i.
Construction of MCMV deletion mutants
M83 and
M84 and rescued
virus r
M83.
To begin characterizing the functions of M83 and
M84 in vivo, single-deletion MCMV mutants were constructed. Insertional
mutagenesis of the MCMV HindIII C region (Fig.
2A) was performed by replacing the M83 or
M84 ORF with the lacZ/gpt cassette (Fig. 2B and C, respectively). As described in detail in Materials and Methods, recombinant plasmids were constructed such that the marker cassette was
flanked by 0.9 to 1.4 kbp of genomic sequence surrounding the region of
the genome to be deleted. Following restriction digestion, these
plasmids were electroporated into NIH 3T3 fibroblasts, which were
subsequently infected with wild-type MCMV K181. Viruses that underwent
homologous recombination between genome and plasmid sequences were
isolated by mycophenolic acid selection and plaque purification.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 2.
Construction of the M83, M83-2, and M84
deletion mutants of MCMV. (A) HindIII restriction map of
MCMV K181 and location of ORFs M82 to M86 in the HindIII
C region. Arrows indicate the transcription direction and sizes of the
ORFs. All ORF lengths are to scale, with the scale (in base pairs)
indicated on the right. Also shown are the positions of restriction
sites important for plasmid construction. Abbreviations: Hind,
HindIII; Eco, EcoRI; RV, EcoRV;
Pst, PstI; Not, NotI. (B) Construction of M83
and M83-2 by homologous recombination between either the p M83KO8
or p M83-2 insert, respectively, and the K181 genome. Identical
shading and cross-hatching indicate homologous regions, while dashed
lines indicate continuation of genome sequences. Indicated by a
horizontal bar above p M83-2 is the 28 bp provided as a
NotI-to-PstI oligonucleotide adapter as described
in Materials and Methods. (C) Construction of M84 by recombination
of homologous sequences of K181 and the insert from p M83KOT-5. The
restriction sites at the borders of some homologous regions have been
changed in the plasmid to facilitate subcloning.
|
|
To restore the M83 ORF in the
M83 virus, we initially used a
protocol in which NIH 3T3 cells were electroporated with a plasmid containing the M83 ORF flanked by 1 to 2 kbp of upstream and downstream sequences and then infected with
M83. Resultant viruses were plaque
purified, and the plaques were stained with X-Gal to identify virus
which had lost the lacZ/gpt cassette by incorporating the M83 ORF, thereby generating the wild-type genome. However, after several repetitions of electroporation and infection, and following the
staining of several thousand plaques, it became apparent that identifying a low-frequency clear plaque in a background of blue
M83
plaques was not practical, particularly since an unacceptably high
percentage of
M83 plaques did not stain blue at the same time as the others.
To solve this problem, we devised a protocol which involved
constructing a viral intermediate that contained the wild-type M83 gene
plus another selectable marker. Using a method described by M. Prichard
and G. Pari (45a), we constructed a cassette expressing the
EGFP and puromycin resistance genes as a single fusion protein for
efficient generation of CMV mutants (see Materials and Methods). We
then assembled a rescue plasmid, pM83Res13.6 (Fig.
3B), such that homologous recombination
would introduce the EGFP-puro cassette and the M82, M83, and M84 ORF
sequences into the
M83 genome (Fig. 3C). The resultant
lacZ+ EGFP+ intermediate M83 rescue
virus was expected to have a relatively high rate of homologous
recombination of M84 direct-repeat sequences (one endogenous and one
introduced on the rescue cassette) (Fig. 3C), and intramolecular
recombination of these sequences in the intermediate virus would delete
the intervening DNA sequences. As a consequence, this virus would
revert back to a LacZ
EGFP
phenotype and
the wild-type HindIII C region would be restored (Fig.
3D). The intermediate LacZ+ EGFP+ virus was
first generated by electroporation of NIH 3T3 cells with linearized
pM83Res13.6, infection with
M83, and puromycin selection.
EGFP+ plaques were picked and used to infect fresh cultures
in the absence of drugs. Viral plaques from these cultures were stained with X-Gal, and LacZ
EGFP
plaques were
isolated and further plaque purified to homogeneity.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 3.
Construction of the M83 revertant r M83, using the
EGFP-puro cassette. (A) DNA sequences of the M83 genome were
recombined in NIH 3T3 cells with homologous sequences (indicated by
identical shading and cross-hatching) in the rescue plasmid cassette
pM83Res13.6 (B). Selected restriction sites used for subcloning or for
reference are indicated with abbreviations as in Fig. 2. Bam,
BamHI. (C) Recombination between both homologous regions
yields an r M83 intermediate virus in which the EGFP-puro cassette
and full-length M83 ORF have been inserted into the M83 genome as
indicated. Intramolecular recombination between M84 direct-repeat
sequences in the r M83 intermediate would be expected to delete
intervening marker gene sequences (bracketed in panel C), resulting in
an EGFP LacZ virus with a wild-type (wt)
HindIII C region (D).
|
|
Genomic DNAs from uninfected cells and from cells infected with the
mutant or revertant viruses were purified for Southern blot analysis.
For analysis of the
M83 and r
M83 genomes, genomic or
HindIII C plasmid DNAs were digested with
BamHI, electrophoresed, and blotted to a nylon membrane. A
4.4-kbp StuI-to-XhoI genomic probe was isolated
from the HindIII C plasmid, 32P labeled by
random priming, and used to probe the blot. For analysis of the
M84
genome and further confirmation of the r
M83 genome structure,
genomic and HindIII C plasmid DNAs were digested with SstI and XhoI and fragments were detected with a
7.6-kbp EcoRV-to-NotI genomic probe. Southern
blot analysis of the HindIII C regions of the
M83,
M84, and r
M83 viruses showed restriction patterns indicative of
the insertion or removal of the lacZ/gpt cassette (Fig.
4 and 5).
The common 0.52-kbp band expected in the plasmid or viral lanes in Fig.
4 was detected upon prolonged exposure of the blot (data not shown). No
wild-type-specific restriction fragments were detected in the
M83
and
M84 lanes after overexposure of the blots, indicating that the
virus stocks were free from contaminating wild-type virus. Similarly,
no bands specific for the r
M83 intermediate or
M83 viruses were
detectable in the r
M83 lanes upon overexposure of the blots,
indicating that the stock of revertants was also homogeneous. In
addition, Southern analysis of the resulting r
M83 virus showed the
wild-type structure when two different restriction digestion schemes
and genomic probes were used (Fig. 4 and 5).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Genomic analysis of M83, M83-2, and r M83
viruses by restriction digestion and Southern blotting. (Left panels)
The restriction maps of the portions of the HindIII C
regions under analysis are shown for the K181, M83, and M83-2
viruses, with arrows indicating the positions, lengths, and directions
of transcription of ORFs. B, BamHI; St, StuI; X,
XhoI. Above each restriction map are shown the lengths (in
kilobase pairs) and positions of restriction fragments detected by the
genomic probe (indicated by the shaded regions). (Right panels) Genomic
DNA was purified from uninfected cells or cells infected with the virus
indicated. Genomic and HindIII C plasmid DNAs were
digested with BamHI, electrophoresed, and blotted. The
4.4-kbp StuI-to-XhoI genomic probe was isolated
from the HindIII C plasmid, 32P labeled by
random priming, and used to probe the blot. The expected 0.52-kbp band
in both panels was visible upon prolonged exposure of the blots.
|
|

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 5.
Genomic analysis of the M84 and r M83 viruses by
restriction digestion and Southern blotting. Details of genomic maps
and DNA preparation are as described in the legend to Fig. 4. Ss,
SstI; RV, EcoRV; N, NotI; X,
XhoI. Genomic and HindIII C plasmid DNAs were
digested with SstI and XhoI prior to
electrophoresis, blotting, and detection with the 7.6-kbp
EcoRV-to-NotI genomic probe.
|
|
Replication of
M83 and
M84 in cell culture.
The roles of
M83 and M84 proteins in MCMV replication were examined by single- and
multicycle replication experiments using
M83 and
M84.
Single-cycle replication experiments measured the accumulation of
extracellular tissue culture virus in NIH 3T3 fibroblasts infected with
K181,
M83, or
M84, or r
M83. We found that the
M84 (Fig.
6A),
M83 (Fig. 6B), and r
M83 (Fig.
6B and C) viruses replicated with wild-type kinetics and that their
peak titers were comparable. When the combined levels of
cell-associated and extracellular virus were measured in a separate
experiment, the growth kinetics and final titers of all three viruses
were also indistinguishable (data not shown). NIH 3T3 cells were also infected at a low MOI in order to examine the replication efficiency and cell-to-cell spread of the mutant viruses. Extracellular virus titers measured after infection with either
M83 or
M84 at an MOI
of 0.05 were identical to those of the parent strain (Fig. 6D). This
finding was consistent with the similar CPE, plaque sizes, plaque
morphologies, and final viral titers obtained during several
simultaneous preparations of K181,
M83, and
M84 stocks (data not
shown). Taken together, these data indicate that the M83 and M84 ORFs
are dispensable for replication in cultured fibroblasts.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 6.
Growth of mutant and revertant MCMVs in NIH 3T3 cells.
All titers presented are the means of the log10 PFU/ml of
the extracellular tissue culture medium of triplicate cultures, with
error bars indicating the standard deviations (SD). (A) Single-cycle
growth of K181 and M84 after infection at an MOI of 3. (B)
Single-cycle growth of K181, M83, and r M83 in NIH 3T3 cells as
described for panel A. (C) Single-cycle growth of K181, M83,
M83-2, and r M83 as described for panel A. (D) Multicycle growth
of K181, M83, and M84 in NIH 3T3 cells infected at an MOI of
0.05.
|
|
Protein expression from mutant and revertant MCMVs.
The
kinetics of protein expression from the various MCMV isolates were
analyzed to determine whether expression of selected proteins
representing the three temporal classes of gene products was grossly
affected in any of the mutants as well as to confirm that the
appropriate MCMV gene products were not expressed in their respective
mutants. For these experiments, NIH 3T3 cells were infected with either
K181,
M83,
M84, or r
M83 at an MOI of 3.5, and at 8, 24, and
48 h p.i., cells were harvested and whole-cell extracts were
prepared as described above.
Western blot analysis using the rabbit M83 antiserum demonstrated the
absence of detectable M83 protein in
M83-infected cells. M83 in
cells infected with K181,
M84, or r
M83 was detectable by 24 h p.i., and its levels were similar in all of these infected cells
(Fig. 7A), although the r
M83 infection
proceeded slightly faster than did the others as judged by CPE
formation and earlier detection of the various proteins examined. Thus,
M83 expression kinetics and levels in the M84 deletion mutant and in
the M83 revertant virus were not significantly affected by the genetic manipulations. We previously showed that M83 is a late gene, with the
corresponding protein being undetectable until 48 h p.i. in infected NIH 3T3 cells by Western blotting (13).
Improvements in detection sensitivity and variations in actual MOI may
account for the earlier detection of M83, at 24 h p.i., in these
studies.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 7.
Western blot analysis of mutant and revertant MCMVs.
Whole-cell lysates were prepared from uninfected or MCMV-infected NIH
3T3 cells harvested at 8, 24, or 48 h p.i. Lysates were
electrophoresed on 7.5% polyacrylamide-SDS gels, and separated
proteins were electroblotted onto nitrocellulose. M83, M84, and M32
proteins were detected with rabbit polyclonal antisera as described in
Materials and Methods. pp89 protein was detected with an antiserum from
BALB/c mice immunized with intradermal injections of pcDNA3-pp89. Bound
antibodies were detected with horseradish peroxidase-coupled anti-mouse
or anti-rabbit antibodies as in Fig. 1. (A) Expression of M83, M84,
M32, and pp89 proteins in NIH 3T3 cells after infection with K181,
r M83, M83, or M84. (B) An independent experiment showing M83
and M84 expression 8 or 48 h after infection with K181, M83, or
M83-2. uninf., uninfected. The positions of molecular mass markers
are shown on the right.
|
|
Protein species reactive to the M84 antiserum were found in all of the
viruses except
M84. Similar to the data shown in Fig. 1, high
levels of M84 protein were detected at 8 h p.i. in the wild-type,
M83, and r
M83 viruses, and M84 protein levels tapered off through
the 48-h-p.i. time point. In the case of the wild-type and r
M83
viruses, the protein appeared to be a doublet, 64 and 66 kDa in size.
However, we noted that the M84 protein in the
M83 virus appeared to
be slightly larger. This aberration was explored by sequencing the M84
gene-lacZ junction in the plasmid used to construct the
M83 virus, p
M83KO8. It was found that the M84 ORF extended beyond
the PstI site junction, 75 bp into the vector sequence used
for construction of the recombination plasmid. The stop codon and the
coding sequence for the C-terminal 3 amino acids of M84 were therefore
replaced with 35 amino acids of the ORF until the first termination
codon was reached. This allowed fusion of an extra 3 kDa of
vector-encoded protein onto the C terminus of the M84 protein,
consistent with the migration pattern observed by Western blotting. In
this experiment and others, we also noted that the level of the M84
fusion protein in the
M83-infected cells was at least twofold higher
at 48 h p.i. than the levels in cells infected with K181 or
M83.
Because
M83 was found to express a mutant form of M84, we were
concerned that we would not be able to determine unambiguously whether
any phenotype found in this virus was due to the absence of the M83
gene product, the presence of the M84 fusion protein, or both. We
therefore constructed a M83 deletion mutant,
M83-2, which contained
the wild-type 3' coding sequence of the M84 ORF. The recombinant vector
p
M83-2 (Fig. 2B) was constructed by inserting an oligonucleotide
adapter into the NotI and PstI sites at the M84
gene and lacZ borders in order to provide the coding
sequence for the carboxy terminus of M84 as well as termination codons. This vector was used for in vivo homologous recombination with MCMV
K181 as described for
M83 and
M84, and Southern blot analysis showed the expected restriction pattern for the replacement of M83 with
the lacZ/gpt cassette (Fig. 4). In addition, the
single-cycle replication kinetics of
M83-2 in NIH 3T3 cells were
found to be identical to those of K181, r
M83, and the first M83
mutant
M83 (Fig. 6C). Finally, Western blot analysis was performed
to determine whether the M84 gene product in
M83-2 was wild type with respect to both its relative mobility on SDS-polyacrylamide gels
and its expression kinetics. As with
M83, M83 protein was not
detectable at any time p.i. in cells infected with
M83-2 (Fig. 7B).
Unlike
M83, however, the expression level and relative mobility of
M84 protein in
M83-2-infected cells were indistinguishable from
those found in K181-infected cells (Fig. 7B). Thus,
M83-2 appeared
to express wild-type M84 protein in the absence of M83 gene product.
Western blot analyses of the products of an IE gene and a late gene,
IE1-pp89 and the M32 gene product, respectively, showed wild-type
kinetics and levels of expression of these gene products in all of the
viruses (Fig. 7A). Taken together, the results showed that neither IE
and late gene expression nor the production of infectious virus was
significantly affected by the absence of the M83 or M84 gene product.
M83 and
M84 are both attenuated for replication in BALB/c
mice, with
M83 showing a specific defect for growth in salivary
glands and lungs.
The roles of M83 and M84 in viral replication in
the host were examined by infection of inbred strains of mice with the
mutant viruses by two different inoculation routes. We first examined the replication of the mutant viruses in the susceptible BALB/c strain
following i.p. infection. Five mice per group were infected with 5 × 105 PFU of tissue culture-derived K181,
M83, or
M84, and on day 4 p.i. the livers, spleens, and kidneys were
harvested. At the time of sacrifice, both the K181- and, to a lesser
degree, the
M84-infected mice exhibited ruffled fur but no hunching
or lethargy, while the
M83-infected mice displayed no morbidity. As
seen in Fig. 8A, titers of
M83 and
M84 in the spleen were reduced more than 11- and 12-fold,
respectively, relative to that of the parent strain. Because virus was
sometimes undetectable in one or more organs of a particular group (as
denoted by the subscript 0 in Fig. 8 and 10), the titers of those
organs were arbitrarily set to the limit of assay sensitivity,
generally 102 PFU/organ, for mean calculations. Thus, fold
reductions of titers in those groups are likely underestimates. In the
liver, similar 11- to 12-fold reductions relative to wild-type titers
were seen for both mutant viruses (Fig. 8A). The titer of
M84 in the
kidneys was 6-fold lower than that of K181, while
M83 titers were at least 13-fold below the wild-type level. Taken together, compared to
the wild type, tissue culture-passaged MCMV, both
M83 and
M84
appear to be growth attenuated in the abdominal target organs.

View larger version (47K):
[in this window]
[in a new window]
|
FIG. 8.
Growth of mutant and revertant MCMVs in BALB/c mice
following i.p. or i.n. inoculation. (A) Five BALB/c mice per group were
inoculated i.p. with 5 × 105 PFU of tissue
culture-derived virus, and resultant viral titers in the livers,
kidneys, and spleens 4 days postinoculation, or in the salivary glands
10 days postinoculation, are shown. Titers represent the means of the
log10 PFU/organ values, with the standard deviations (SD)
being shown by error bars. Values above each bar indicate the fold
reductions of the nonlogarithmic mean titers (i.e., PFU/organ) of that
group relative to the corresponding K181-infected controls. The
subscript 0 indicates that in at least one organ in that group, virus
was undetectable, and that the titer of that organ was set to the limit
of detection for calculation purposes. (B) Day 4 spleen and day 10 salivary gland titers of four mice per group inoculated i.p. with K181,
r M83, M83, or M83-2 as described for panel A. (C) MCMV titers
in the lungs and salivary glands of four mice per group 14 days
following inoculation i.n. with 1.5 × 105 PFU of
virus.
|
|
Replication of
M83 in the salivary glands, however, was severely
attenuated, and these titers were 600-fold lower than those of K181 on
day 10 p.i. (Fig. 8A). This decrease in virus titer in the
salivary glands was not due to the expression of the M84 fusion
protein, since the
M83-2 virus, which is wild type with respect to
M84 protein expression, as determined by Western blotting, replicates
in the spleen and salivary glands to levels similar to those of
M83
(Fig. 8B). By comparison, the level of replication of
M84 in
salivary glands was approximately 12-fold lower than that of the parent
strain. Independent experiments in which the inoculation dose of
M83
was 105 PFU or lower showed that the level of attenuation
of replication in the salivary glands varied between 150- and 600-fold
(Fig. 8B and data not shown). Following injection of 5 × 105 PFU of
M83, the titers were still reduced by
approximately 600-fold, but by increasing the i.p. inoculation dose
5-fold to 2.5 × 106 PFU for each of the viruses,
titers of
M83 in the salivary glands were reduced only 25-fold
compared to the K181 titer (data not shown). As expected, we found that
the rescue of M83 expression in the r
M83 virus restored wild-type
replication levels in the spleen and salivary glands following i.p.
infection (Fig. 8B).
Because the route of administration of MCMV has been shown to be
important in terms of the nature and severity of the infection (28), we assessed the replicative abilities of the mutant
viruses following infection by a nonparenteral route. Four BALB/c mice per group were given i.n. inoculations of 1.5 × 105
PFU of tissue culture-derived virus, and on day 14 p.i., lungs and
salivary glands were harvested and assayed for infectious MCMV. As
shown in Fig. 8C, the replication of
M83 in salivary glands was
attenuated approximately 90-fold relative to that of K181, while
M84
titers were on average 5-fold lower than those of the wild type.
Similarly, virus titers in the lungs of the
M83-infected mice were
at least 27-fold lower than those of the K181-infected mice, and
M84
replication in the lung was reduced approximately 5-fold compared to
that of the wild type. Thus, following inoculation of BALB/c mice by
either a parenteral or mucosal route, replication of
M83 in lung and
salivary gland tissues was significantly reduced below wild-type levels.
M83 and
M84 show patterns of restricted replication in
C3H/HeN and 129/J mice similar to those seen in BALB/c mice.
The
ability of MCMV to replicate in vivo has been found to depend on the
strain of mouse examined (22). We therefore tested the
growth of the MCMV mutants in an inbred mouse strain highly resistant
to MCMV. Four C3H/HeN female mice per group were infected with
M83
or
M84 by inoculation of either 1.5 × 106 PFU
(i.p.) or 1.5 × 105 PFU (i.n.) of tissue
culture-derived viruses. Because C3H/HeN mice are able to effectively
limit MCMV replication in the abdominal organs, and because only tissue
culture-derived virus was used for these experiments, salivary glands
were the only tissue examined for viral replication in this strain.
As expected, we observed no morbidity in the C3H/HeN mice after
infection. K181 titers in the salivary glands following i.p. inoculation reached an average of 106.9 PFU/organ, while
titers resulting from
M83 and
M84 infection were approximately
360- and 5-fold lower, respectively (Fig.
9). Moreover, replication of
M83 in
the salivary glands following i.n. inoculation resulted in a titer that
was approximately 64-fold lower than that resulting from K181
infection. The average
M84 titer, by comparison, was only 1.7-fold
below the wild-type level. Therefore, the relative levels of
attenuation of the mutant viruses in the salivary glands of C3H/HeN and
BALB/c strains of mice appear similar.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 9.
Growth of mutant MCMV in the salivary glands of C3H/HeN
mice. Shown are MCMV titers 10 days following i.p. inoculation with
1.5 × 106 PFU of tissue culture-derived virus and 14 days following i.n. inoculation with 1.5 × 105 PFU of
virus. Means, standard deviations (SD), and fold-reduction values above
each bar are as described in the legend to Fig. 8.
|
|
Lastly, we examined the replication of the mutants in the
MCMV-sensitive inbred mouse strain 129/J. We have found the 50% lethal
dose LD50 of salivary gland-derived MCMV in the 129/J
female mice to be roughly 10-fold lower than that in the moderately
sensitive BALB/c strain (data not shown). Four 129/J female mice per
group were inoculated i.p. with 5 × 105 PFU of the
mutant viruses. On day 2 p.i., the mice infected with K181 or
M84 exhibited ruffled fur, but no signs of morbidity were observed
by day 3. On day 4, mice were sacrificed and organs were removed for
MCMV titer determination. Spleens of mice infected with K181 were
noticeably smaller and more necrotic than those from the
M83- or
M84-infected mice, a phenomenon seen after infection of various
inbred strains of mice with virulent MCMV (42). MCMV titers
in the 129/J spleens were 103.1 PFU/spleen for the
K181-infected mice and only two- to threefold lower in the
M83 and
M84 groups (Fig. 10A). In contrast,
a greater than 10-fold reduction in
M83 titer compared to that of
K181 was seen in the liver. A greater than threefold reduction in titer below that of the wild type was seen for
M84 in this organ. More importantly, 10 days after i.p. infection, titers of
M83 in the salivary glands were 75-fold lower than those observed in K181-infected mice (Fig. 10A). As with the other strains of mice tested,
M84 replicated to an approximately sixfold lower level than the parent virus.

View larger version (31K):
[in this window]
[in a new window]
|
FIG. 10.
Growth of mutant MCMV in 129/J mice following i.p. or
i.n. inoculation. (A) MCMV titers of four 129/J mice per group
following i.p. inoculation with 5 × 105 PFU of tissue
culture-derived virus. Organ harvest days, titer value calculations,
and fold reduction values above each bar are as described in the legend
to Fig. 8. (B) MCMV titers in the lungs and salivary glands of four
mice per group 14 days following i.n. inoculation with 2.5 × 105 PFU of virus. SD, standard deviation.
|
|
When 129/J mice were inoculated i.n. with 2.5 × 105
PFU of the three viruses,
M83 replication was reduced 67-fold in the
salivary glands and at least 116-fold in the lung relative to that of
the wild-type virus (Fig. 10B). In contrast, the titers of
M84 in salivary gland and lung tissues were reduced only 17- and 3-fold, respectively, below those of the wild-type controls. When all of the
data on virus replication in organs are taken together, both
deletion-mutant viruses appear to be attenuated 2- to 10-fold in
replication in abdominal organs compared to the parent virus. More
importantly,
M83 is markedly attenuated 25- to 600-fold in the
salivary glands following i.p. or i.n. infection, and following i.n.
inoc